New living systematic review and network meta-analysis compares the effects of drug prophylaxis for covid-19. Use our interactive #BMJInfographic as a visual guide to the evidence @will_s_t
https://t.co/Jza8h335ap
Our updated living network meta-analysis (LNMA) on drug treatments for #COVID19 is now out!
https://t.co/2XQrpNYcck
The LNMA informed the latest @WHO guidance recommending against #ivermectin.
https://t.co/gm0SbcoYmY
https://t.co/Z5xFpUzM57
1/ It is out! 🤩 another @WHO Living Guideline on #COVID19 management, at this time on the role of the hydroxychloroquine (HCQ) as prophylaxis
📢 Strong recommendation AGAINST the use of HCQ for COVID-19 PREVENTION
Yes, I know, HCQ is so...
https://t.co/WWSESW5JCU @bmj_latest
It's here! The first iteration of our living NMA on drugs to prevent #COVID19 is out on @medrxivpreprint.
Includes RCTs on hydroxychloroquine and ivermectin prophylaxis.
https://t.co/AadMqZadcJ
Hydroxychloroquine did not reduce rate of infection, hospitalization, or mortality but more people stopped the drug because of adverse events.
The studies on ivermectin so far have been small and therefore whether ivermectin reduces infection remains uncertain.